BioSpace News Archive

BD, a leading global medical technology company, is pleased to announce the integration of the BD HealthSight™ Analytics Solutions in Eastern Health facilities.

SK Life Science, Inc., announced that the results of the long-term, open-label extension (OLE) of a randomized, double-blind, placebo-controlled study (C017) of XCOPRI® (cenobamate) were published online in the journal Neurology.

Susan G. Komen ® , the world’s leading breast cancer organization, is awarding $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions in the U.S. that are focused on improving patient outcomes.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m. London time (8 a.m. EDT).

Propanc Biopharma, Inc. today announced that the results from a small trial of just 18 rectal cancer patients in complete remission using an immunotherapy called dostarlimab are “impressive,” whilst acknowledging there’s more work to be done.

In a presentation titled “Reaching the goal with higher speed and confidence”, CEO Dr Werner Lanthaler and CFO Enno Spillner presented Evotec SE’s current strategic, scientific and technological developments, highlights of the 2021 business year and the commitment to sustainability/ESG.

A team of investigators from Texas Heart Institute, Texas Children’s Hospital and Baylor College of Medicine uncovered new insights into the mechanisms underlying the progression of congenital heart disease (CHD) ― a spectrum of heart defects that develop before birth and remain the leading cause of childhood death.

Despite overall improvements to care for a heart attack, women are less likely to receive timely treatment, according to a new study in Annals of Emergency Medicine.

BioAxone BioSciences, Inc., a clinical stage biotechnology company committed to discovering and developing drugs for neurological conditions, today announced that a new patent has been issued for BA-210, a Phase 3-ready pro-regenerative drug candidate for the treatment of spinal cord injury.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced new, compelling efficacy data supporting the late-stage, Phase 3 development of XEN1101.